BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sun Pharmaceutical Industries readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sun Pharmaceutical Industries's d
 rugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07282743-274@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Utreglutide: Phase 2 readout est. (NCT07282743)
DESCRIPTION:Utreglutide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of
  GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/utreglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07282743
URL:https://assetmemo.bio/drug/utreglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102511-1049@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07102511)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Study to Evaluate the Efficacy and Safety of Lerodalc
 ibep in Children 6 to 17 Years\, With Heterozygous FH\nEstimated primary c
 ompletion: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07102511
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04991116-99@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ilumya (tildrakizumab): Phase 3 readout est. (NCT04991116)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 3\, Psoriatic Arthritis.\nStudy:
  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients 
 With Psoriatic Arthritis\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tildrakizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04991116
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775339-1049@assetmemo.bio
DTSTAMP:20261121T005738Z
DTSTART;VALUE=DATE:20310731
DTEND;VALUE=DATE:20310801
SUMMARY:Lerochol (Lerodalcibep): Phase 3 readout est. (NCT07775339)
DESCRIPTION:Lerochol (Lerodalcibep)\, phase 3\, Atherosclerotic Cardiovascu
 lar Disease.\nStudy: Long-Term Efficacy and Safety of Lerodalcibep in Chil
 dren and Adolescents With Familial Hypercholesterolemia\nEstimated primary
  completion: 31 July 2031. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lerodalcibep#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07775339
URL:https://assetmemo.bio/drug/lerodalcibep#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
